Bergua Burgués, Juan Miguel | Hematología y Hemoterapia |

Resultados: 249
Tipo Título / Nombre Autor(es) Año
Treatment with FLAG-IDA or FLAGO-IDA regimen in adult patients with relapsed/refractory acute myeloid leukemia. Retrospective analysis of the PETHEMA AML Registry Bergua Burgués J, Montesinos P, Martínez Cuadrón D, Serrano J, Fernández P, Rayón C, Sayas MJ, Barrios M, Pérez C, _Herrera P, Martínez M, García R, Gayoso J, Pérez Encinas M, [et.al] 2013
Flow cytometric CD38 expression on CD34+ cells as a simple diagnostic test in myelodysplastic syndromes (MDS) Bañas Llanos MH, Ibañez Espacio F, Martín-Aguilera C, Arcos Carmona MJ, Carnicero F, Cabrera C, Martín Mateos ML, Fernández H, Prieto J, Bermejo N, García-Blanco MJ, Bergua Burgués J 2013
Azacytidine 75 mg/m2 ×5 day in high-risk myelodisplastic syndromes and acute myeloid leukemia refractory/relapsed patients Bergua Burgués J, Arcos MJ, Carnicero F, Prieto J, Cabrera C, Martín-Mateos ML, Fernández H, Bañas H, Ibañez F, Martín-Aguilera C, Siguenza R, Bermejo N, García-Blanco MJ, Sánchez J 2013
Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab) Ribera JM, García O, Grande C, Esteve J, Oriol A, Bergua J, González-Campos J, Vall-Llovera F, Tormo M, Hernández-Rivas JM, García D, Brunet S, Alonso N, Barba P, Miralles P, Llorente A, Montesinos P, Moreno MJ, Hernández-Rivas JÁ, Bernal T. 2013
Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels Sánchez-Correa B, Bergua JM, Campos C, Gayoso I, Arcos MJ, Bañas H, Morgado S, Casado JG, Solana R, Tarazona R. 2013
Leucemia aguda promielocítica Bergua J 2012
Azacitidine As Front-Line Therapy in AML: Results From Spanish National Registry. Alma Study Investigators Ramos F, Martínez-Robles V, Bargay J, Deben G, Garrido A, Serrano J, Salamero O, Bergua J, Colado E, García R, Pedro C, Redondo S, Tormo M, Bonanad S, Diez-Campelo M, Pérez-Encinas M, Fuente de la A, Xicoy B, Falantes J, Font P, González-López TJ, Martin-Núñez G, Montesinos P, Sánchez-Guijo FM 2012
Understanding recurrent thrombosis of antiphospholipid syndrome. Fernández H, Bermejo Vega N, Martín Aguilera C, Carnicero F, Ibañez Espacio F, Arcos Carmona MJ, Baña E, Cabrera Silva C, Prieto J, García Blanco MJ, Martín Mateos M, Bergua Burgues JM 2012
Dose-Adjusted EPOCH Plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell, with Analysis of Germinal Center and Activated B-Cell Biomarkers. A Phase IV Study Conducted by the Spanish PETHEMA Group Purroy N, Bergua J, Gallur L, Prieto J, Sancho JM, López L, García-Marco JA, Montes S, López A 2011
Dose-adjusted EPOCH plus Rituximab in untreated patients with poor prognosis large B-cell, with analysis of germinal center and activated B-cell biomarkers. A phase IV study conducted by the Spanish PETHEMA Group Purroy N, Bergua J, Gallur L, Prieto J, Sancho JM, López L, García M, Arco JA, Montes S, López A 2011